Poolbeg Pharma plc: POLB 001 patent portfolio strengthened through granting of US patent
Key highlights · Patent granted for use of certain p38 MAP kinase inhibitors for the treatment of hypercytokinaemia · Allows for use in combination with an antiviral agent · Patent enhances the robust IP portfolio protecting Poolbeg’s growing pipeline 8 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that […]